GSK/Genmab seek US label expansion for Arzerra
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and its partner Genmab are seeking the FDA's approval to expand the use of Arzerra (ofatumumab) as a first-line treatment of chronic lymphocytic leukaemia (CLL).